YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer (NCT07461454) | Clinical Trial Compass
RecruitingPhase 3
YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer
China376 participantsStarted 2026-03-17
Plain-language summary
The study will evaluate the safety and efficacy of YL202, when compared with treatment of physician's choice (eribulin, capecitabine, vinorelbine, gemcitabine or sacituzumab govitecan) in participants with unresectable locally advanced, recurrent or metastatic hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer who had failed at least one line of chemotherapy.
Who can participate
Age range
18 Years – 75 Years
Sex
FEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Have been informed of the study before the start of the study and voluntarily sign name and date on the informed consent form.
. Histologically and/or cytologically confirmed locally advanced or metastatic HR+/HER2- breast cancer who are not candidates for curative surgery or radiotherapy.
. Patients who had failed at least one line of systemic chemotherapy in unresectable locally advanced, recurrent, or metastatic stage.
. Have at least 1 extracranial measurable lesion as a target lesion per RECIST 1.1.
. Tumor tissue samples can be provided at the time of diagnosis of locally advanced or metastatic tumors.
. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 1.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Progression-free survival (PFS) assessed by BIRC per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.
. Have Adequate organ and bone marrow function within 7 days prior to the first dose.
. Female patients of childbearing potential must agree to use highly effective contraception from screening throughout the duration of the study and for at least 6 months after the last dose of study drug.
Exclusion criteria
. Have prior treatment with an agent targeting HER3.
. Have prior treatment with topoisomerase I inhibitor or an ADC that consists of topoisomerase I inhibitor.
. Have insufficient washout period for prior anticancer therapy prior to first dose of the study drug.
. Have major surgery (excluding diagnostic surgery) within 4 weeks prior to the first dose of study drug or anticipation of major surgery during the study.
. Leptomeningeal metastases or carcinomatous meningitis, spinal cord compression.
. Have uncontrolled or clinically significant cardiovascular and cerebrovascular disease.
. Have clinically significant concomitant pulmonary diseases.
. Have uncontrolled pleural effusion, abdominal effusion.